One shot to stop clots? new drug tested in knee surgery patients

NCT ID NCT06180889

Ongoing Prevention Sponsor: Suzhou Alphamab Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a new drug called KN060, given as a single intravenous dose, to prevent blood clots in people having total knee replacement surgery. It compares KN060 to the standard treatment enoxaparin, which requires daily injections. The trial involves 241 adults and is currently active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KN060 (a single-dose intravenous infusion) compared to enoxaparin (daily injections)
What this could lead to: If successful, KN060 could offer a simpler, single-dose option to prevent dangerous blood clots after knee replacement surgery.
What could go wrong: This is an early phase 2 trial with only 241 participants, so results may not apply to everyone. Bleeding risk is a key safety concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE ARTHROPLASTY, TOTAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KNEE ARTHROPLASTY, TOTAL

Contacts and locations

Locations

Shanghai Sixth People's Hospital

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.